home about_us science products news_events  

Creatine Kinase Enzyme System
Scientific Studies



The Avicena Group is strategically focused on regulating the body's cellular energy processes by utilizing certain proprietary biochemicals. The company is particularly interested in those biochemicals that influence the body's natural creatine kinase (CK) and creatine transporter (CT) systems to effectively regulate cellular energy.

Based on its scientific knowledge of the body's energy regulation processes, the Avicena Group has developed two proprietary cellular energy platforms:

  • The Cellular Energy Modulation Platform, which modulates the body's natural creatine kinase system; and
  • The Cellular Energy Transfer Platform, which emulates the body's natural creatine transporter system

The Avicena Group's cellular energy modulation platform is of critical therapeutic importance due to the fact that it targets the CK enzyme. This enzyme is responsible for regulating energy in those tissues that require intermittently high and fluctuating energy levels. Those tissues that are most reliant on CK for cellular energy include the skeletal muscles, the heart, the brain, the retina, and various skin tissues.

The company's cellular energy transfer platform emulates the specific creatine transporter system, which is responsible for mediating the transport of creatine from the blood stream across the blood-brain barrier to the active brain cells.

In recent years, it has been demonstrated that a variety of debilitating neurological and neuromuscular diseases are caused primarily by the body's inability to produce or deliver sufficient cellular energy. This lack of cellular energy causes certain cells to degenerate at a more rapid rate, often resulting in the symptoms of a particular disease.

The Avicena Group's extensive product pipeline is based on the company's proprietary and in-depth understanding of the body's CK and CT systems and the role each plays in regulating and transporting cellular energy to prolong cellular life and/or to protect against cell injury and cell death. Presently, the Avicena Group, in collaboration with several leading universities, is conducting a number of clinical studies designed to demonstrate the ability of its drug candidates to ease the symptoms of various diseases.